Brachytherapy

Brachytherapy also known as seed implant therapy or interstitial radiation therapy is a least invasive procedure involving implantation of small (sized like a rice grain) lasting radioactive seeds within the prostate where they help in irradiating cancer from within the gland. Radioactive seeds on implantation are so small-sized that they are not sensed by the patient. Based on conditions, radioactive palladium or iodine would be employed.

Prior to implantation of the seeds, the patient is anaesthetized. Insertion of needles holding the seeds are then done via the perineum skin (lying between scrotal and anal area) employing ultrasound supervision. These seeds stay in the prostate, where they emit contained radiation for some months to annihilate the prostate cancer.

Seed implantation is an effectual treatment for males having prostate cancer limited to a small area. No operative incising is needed during the procedure and it provides briefer recuperation periods. It could be performed on an outpatient basis with majority of the patients leaving the very day they received the treatment.

Cryotherapy

Cryotherapy eradicates the disease by a process of freeze-killing cancer cells in the prostate gland. After a patient has been anaesthetized, a surgeon would insert needles within the prostate gland via the perineum skin. These needles create extremely low temperatures and help in freeze-obliterating the complete prostate, inclusive of any malignant tissue in it.

Cryotherapy employs really fine needles for producing ice orbs of below-zero temperatures. Ultrasound helps the surgeon in accurately controlling the volume and form of the ice orbs and monitoring the freezing.

Cryotherapy is a choice for those prostate cancer patients intending on avoiding major surgical intervention or not keen on taking chances by adopting watchful wait policy. This procedure could help in treating those patients in the intermediary and elevated risk category along with those who have found no benefits from past radiation treatments.

Cryotherapy could be re-performed in case needed or employed as a secondary treatment in case other key treatments are unsuccessful.
The key risk linked with this procedure is impotence as for ensuring total annihilation of cancerous cells, the objective is freeze-killing the tissues past the prostate that could affect nerve clusters linked with erection located near the prostate.

In majority of the cases, the procedure last lesser than 2 hours and least discomforting sensation and pain felt with mobility reinstated the same day.
Side effects of this procedure could be moderate-ranging pelvic discomfort, bloody urine, mild-ranging urinary exigency, swelling in scrotum. All these generally subside in some weeks and recovery to normally functioning bowel and bladder is possible.

EBRT Procedure

EBRT or external beam radiation therapy employs a machine targeting a ray of ionizing irradiation on the malignant tissues. It appears alike undergoing X-rays, however taking more time. The procedure harms heritable matter in all cells that divide within the targeted lesions thus averting cell growth and their eventual death.

EBRT performed on an outpatient basis is a choice for those wherein cancer is restricted to prostate gland.

Hormonal Deprivation Therapy

Male hormone testosterone is the key stimulus for all prostate cells. A few forms of prostate cancer cells in fact need elevated dosages of this hormone and on its elimination via hormonal therapy could provisionally slacken prostate cancer cells from growing however not stopping them.

Hormonal deprivation therapy is of three key types:

• Operative Castration
  This non-reversible method involves removal of testicles via procedure known as orchiectomy. A fairly simple method performed under influence of local anaesthesia and patient could be given discharge from hospital the same day of surgery though in a number of situations, the patient would need to be hospitalized.

• LHRH Therapy
  It involves administration of luteinizing hormone-releasing hormone or LHRH generally taken via oral course and help in preventing testicles from manufacturing male hormone. This treatment spares the testicles and functions analogous to operative castration.

• Combined androgen blockage
  It comprises oral administration of female hormone estrogen for halting testosterone production.

A plummet in hormone level could have an effect on cancerous cells even among those who have metastasized past their initial site. This treatment could help in controlling prostate cancer for many years. Despite having undergone surgical castration, adrenal glands would help in compensating for testicles being removed by manufacturing greater levels of male hormone. Despite testicular removal, a man would require taking medicines for blocking flow of testosterone.

Side effects of hormonal therapy comprise of: turning impotent, lost libido, hot flashes, weight increase, weariness, lowered brain functioning and lost muscular mass.

For performing a radionuclide bone scan a miniscule quantity of radioactive matter is administered as an intravenous shot after which the material would settle in the bone tissue that has faced damage all through the skeletal system in the span of a few hours.

The person is then requested to lay flat on a table for nearly thirty minutes during which time a specialised camera identifies the radioactive substance and produces an image of the skeletal structure.

Regions where the bone tissue have been damaged due to the cancer presence are visible as hot spots on the skeletal structure as they are drawn to radioactivity and thus are indicative of the existence of metastatic cancer. However, even in case a person is arthritic or is having other kind of bone ailments would also exhibit analogous hot spots in his/her skeleton during the scan. To exclude the presence of other non-cancer related conditions, the doctor would employ other methods of imaging like basic X-rays, CAT or MRI scanning for getting a clearer view of the regions that are lighting up, or the doctor might also draw biopsy samples from the bone.

The shot is slightly discomforting component of the scanning method. However, the radioactive matter is excreted out of the system in a span of the subsequent couple of days. As infinitesimal quantity of radioactive matter is employed hence it holds negligible risk to the concerned person.

ProstaScint Scan

Analogous to the radionuclide bone scan, the ProstaScint scan employs a shot of less amounts of radioactivity for detecting cancer metastasis that has grown past the prostate. Although the duo tests search for regions of accumulation of radioactive matter, however have diverse means of carrying it out.

The radioactive matter used in ProstaScint is drawn to the prostate cells and is joined to the monoclonal antibody – a form of synthetic protein which detects and affixes to a certain material in this scenario to the PSMA or prostate-specific membrane antigen that is present in elevated amounts in healthy and malignant prostate cells.

The benefit of undergoing this test is that it could detect prostate cancer cells present in the non-bony organs of the body. As the antibody merely adheres to the prostate cancer cells hence there is no likelihood of anomalous outcomes.

This scan is suggested for those males that have been lately detected with prostate cancer. However, it could be beneficial subsequent to treatment in case there is a surge in blood PSA levels and other testing methods are unable to detect the precise site of the cancer.

The presentation of these findings by Mayo Clinic was put forth at the North Central Section of the American Urological Association in Scottsdale, Ariz. The findings were derived from a vast group study of men residing in Olmsted County, Minn. The researchers arbitrarily picked 616 men in the age groups of 40-79 years that didn’t suffer from prostate disease. The patients were entrants for assessments in a 2-yearly interval time period lasting for a span of seventeen years that comprised of PSA testing and measuring prostate volume employing ultrasound for ascertaining variations in prostate disease.

Rodney Breau, M.D., a Mayo Clinic urologic oncology member who headed the study stated that one of the crucial benefits of this vast group study is that the men have taken part in the study that lasted for seventeen years. Due to the long-drawn nature of the study, the researchers had the chance to scrutinise the protracted association in-between prostate development, variation in PSA and how prostate cancer develops.

From the 616 men under the study, prostate cancer was observed to develop in about 9.4%, i.e., 58 men. Men detected with prostate cancer had a swifter rate of increase in PSA levels, i.e., 6 % annually in comparison to the men not detected with prostate cancer (3.3% annually). But, the enlargement in prostate size was analogous between these two sets with a median variation of 2.2% annually.

PSA is a substance manufactured in the prostate gland. Usually, minute quantities of PSA make an entry in the blood stream. An elevated level of PSA or a sudden surge in amounts of PSA could suggest the likelihood of cancer.

Dr. Breau stated that their quest was to find solutions to the query about whether surging PSA levels could be elucidated by a comparative rise in prostate size. He further stated that their data suggested that men irrespective of the presence or absence of prostate cancer had analogous rates of prostate growth. In case the PSA levels are rapidly increasing, then a prostate biopsy would be needed for determining the presence of prostate cancer. He pointed out that evaluation of change in the size of the prostate must not have an influence on the choice to undergo biopsy.

Researchers aimed at ascertaining whether administering elevated radiation dosages using proton beam therapy could lead to early detrimental side effects to the urinary function within the GU or genitourinary system and the rectal functioning within the GI or gastrointestinal system.

Proton therapy is quickly garnering immense popularity as a potent prostate cancer treatment, but it is fuzzy as to whether the long-standing results of proton therapy would surpass those attained by other treatment methods. These procedures were intended to create yardstick outcomes with proton therapy offered at comparatively elevated every day dosages.

Nancy Mendenhall, M.D., the author of the study and the medical director from the University Of Florida Proton Therapy Institute, Jacksonville, Fla., stated that presently they have found that early tolerance of proton therapy has appeared to be promising with a minimal rate of urinary and rectal noxious side effects. She mentioned that the study proves that proton beam therapy was a viable choice among prostate cancer patients with diminutive chances of any side effects to the urinary and rectal functioning.

Proton beam therapy is a kind of external beam radiation therapy that employs protons instead of photons (X-ray beams) for treating particular forms of cancer and other ailments. The physical features of proton beam therapy allow easier delivery of radiation to the tumor with lesser-intensity radiation being passed to the adjoining normal tissues.

In the course of an external beam radiation therapy, a radiation shaft (X-ray or protons) is passed via the skin reaching the malignant growth and it’s nearest adjoining area for destroying the major tumor growth and any of the adjacent cancer cells.

During the time spans from August 2006 till October 2007, there were 212 prostate cancer entrants for 1 of the 3 forthcoming trials for receiving proton therapy. Those patients in the high-risk category were also given the chemotherapy drug – docetaxol, subsequent to which hormone therapy was offered to them.

The researchers had follow-up session with these patients subsequent to treatment for no less than a year’s time to keep tabs on the scores of genitourinary and gastrointestinal toxicity employing both the IPSS (International Prostate Symptom Scores)  and CTCAE, v.3 (Common Toxicity Criteria for Adverse Events) in case of each of the patients that underwent the trial.

The outcome revealed that there was negligible early genitourinary and gastrointestinal toxicity on prospective trials of proton therapy. Lesser than 1% of patients faced Grade 3 gastrointestinal toxicities with the commonly observed side effects being least amount of rectal bleeding that was linked to the section of the rectal wall that received the series of radiation dosages.

The frequency and the extent of severity of the rectal signs were additionally affected by colonoscopic intercessions subsequent to treatment.

Dr. Mendenhall appeared quite optimistic with the outcome of their study and further added that though there were a number of toxicities that might be occurring later on, the researchers were highly delighted with the early toxicity scores as compared to the other treatment choices. Additional follow-up would be needed in such patients for ensuring that these men didn’t experience any kind of side effects that might surface years subsequent to the treatment.

The study showed that those spending major part of their professional lives being seated were nearly thirty percent more prone to being detected with the ailment as compared to those having energetic and active jobs.

Examination of forty-five thousand men in the age group of 45-79 years that had vastly physical jobs were twenty-eight percent less prone to developing the ailment as compared to those men spending majority of their professional lives doing desk jobs.

However, the British Journal of Cancer reported that those men who remained seated for half of the entire time at work had a twenty percent lowered risk as compared to men that remained sedentary for the entire span of their working hours.

Other kinds of physical exercise also seemed to make a difference, for instance men that engaged in cycling and walking for more than one hour during the day had a fourteen percent reduced risk as compared to those who did walking or cycling for forty minutes or lesser.

Though regularly exercising is suggested for overall optimal health, proof of its safeguarding effects against prostate cancer has been deficient till date.

The scientists from the Karonlinska Institute, Sweden stated that it has become increasingly evident that exercising among young and middle-aged men is known to have a major affect on their risk of developing cancer.

The scientists are still unclear as to why exercise has a defensive action against the ailment, but deduce that it causes major alterations in the levels of particular hormones related to cancer, inclusive of testosterone.

The scientists have reached a conclusion based on the discoveries from the study that not being seated for most of the working hours or job-related activity and daily lengthy periods of the main part of dynamic living (taking walks or cycling) might be related to lowered prostate cancer occurrence.

The scientists have added that their findings that might have major health inferences in averting prostate cancer, would need additional corroboration by other ingenious studies.

Earlier studies have indicated that men dietetic intake replete with fruits and veggies could lower the risk of the ailment that is known to affect nearly thirty-five thousand men in Britain annually.

Dr. Helen Rippon from the Prostate Cancer Charity stated that it has been common knowledge that staying physically active lowers the chances of developing cardiovascular ailments, but now it is quite lucid that it could even lower the risk of contracting other diseases.

This study suggests that men belonging to all ages must attempt at staying active for at least an hour’s time on a daily basis. This does not translate to the rigorous calorie-burning sessions at the gym every day; as even taking walks or cycling would do absolutely fine.